
15
16
COMPOUNDER
22
12
COMPOUNDER
22
14
COMPOUNDER
22
22
22
22
22
18
23
10
28
DISPLAY
KEYBOARD
25
HOSPITAL COMPUTER
22
COMPOUNDING COMPUTER
22
16
COMPOUNDER
26
20
24
HOSPITAL A
HOSPITAL B

FIG. 1


146
DETERMINE THE NUMBER OF COMPATABILITY METAGROUPS. 'N' (RINSES) (14)
152
ARE LIPIDS INCLUDED IN THE FINAL BAG? (15)
Y
154
ARE LIPIDS REQUIRED TO BE FIRST, LAST, OR OPTIMIZED? (16)
L
160
FIRST OR OPTIMIZE
F,O
156
N
158
N
128
DOES FINAL BAG ALREADY CONTAIN LIPIDS? (10)
Y
130
DO WE CARE ABOUT LIPID HAZE? (11)
N
132
Y
136
WARN AT LABEL PRINT ABOUT LIPID HAZE (55)
138
USING SOLUBILITY/ COMPATIBILITY GENERAL RULES, BREAK INTO COMPATIBILITY GROUPS AND PROCEED TO CALCULATE COMPOUND WITH RINSES FROM FINAL BAG. (12)
NO
#0
134
COMPOUND WILL NOT BE PREPARED. (48)
110
IF PRESCRIPTION CONTAINS LIPIDS, ARE THEY REQUIRED TO BE FIRST IN THE FINAL BAG? (USER SETTING) (4)
Y
114
DETERMINE THE NUMBER OF COMPATIBILITY METAGROUPS. 'N' (RINSES) (14')
116
SEQUENCE LARGE VOLUME TRANSFERS WITH LIPIDS FIRST USING GENERAL RULES OF MIXING TPNS. (5)
118
112
N
122
DETERMINE THE NUMBER OF COMPATIBILITY METAGROUPS. 'N' (RINSES) (14')
124
SEQUENCE LARGE VOLUME TRANSFERS WITH LIPIDS LAST USING GENERAL RULES OF MIXING TPNS. (6)
126

FIG. 4C



STATE VARIABLES FOR FLOW

METAGROUPS: SET IN BOXES 14, 14'
LIPID SEQUENCE (FIRST, LAST, OPTIMIZE): TESTED IN BOXES 4,16,26
LIPIDS IN PRESCRIPTION (YES, NO): TESTED IN BOXES 15, 24
LIPIDS ALREADY IN BAG (YES, NO): TESTED IN BOX 10
LIPID HAZE UNACCEPTABLE (YES, NO): TESTED IN BOXES 11,51,53



FIG. 4D